ENLIBRIUM

enlibrium-logo

Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production. Enlibrium was founded based on technology exclusively licensed from UCLA and developed in laboratories headed by Michael Jung, Ph.D. and Richard Pietras, M.D., Ph.D. Enlibrium's investors are Avalon Ventures, TPG Biotech, Correlation Ventures and Osage University Partners.

#People #Financial #More

ENLIBRIUM

Industry:
Energy Health Care Medical

Founded:
2015-01-01

Address:
San Diego, California, United States

Country:
United States

Total Employee:
1+

Status:
Active

Total Funding:
15 M USD


Current Employees Featured

not_available_image

Michael Jung
Michael Jung Founder @ Enlibrium
Founder

not_available_image

Richard Pietras
Richard Pietras Co-Founder @ Enlibrium
Co-Founder

Founder


david-campbell_image

David Campbell

not_available_image

Michael Jung

not_available_image

Richard Pietras

Investors List

tpg-biotech_image

TPG Biotech

TPG Biotech investment in Series A - Enlibrium

avalon-ventures_image

Avalon Ventures

Avalon Ventures investment in Series A - Enlibrium

osage-university-partners_image

OUP (Osage University Partners)

OUP (Osage University Partners) investment in Series A - Enlibrium

correlation-ventures_image

Correlation Ventures

Correlation Ventures investment in Series A - Enlibrium

More informations about "Enlibrium" on Search Engine